SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics, Inc. to Present at the 8th Annual JMP Securities Healthcare Conference
July 8, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Presentation of Pre-Clinical Data on the Combination of TG-1101 and TGR-1202 at the International Conference on Malignant Lymphoma, Lugano, Switzerland
June 20, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Presentation of Pre-Clinical Data on the Combination of TG-1101 and TGR-1202 at the International Conference on Malignant Lymphoma, Lugano, Switzerland
June 19, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Clinical and Pre-Clinical Poster Presentations for TG-1101 and TGR-1202 at the European Hematology Association Meeting in Stockholm, Sweden
June 17, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients With Rituximab Relapsed/Refractory Non-Hodgkin’s Lymphoma
June 3, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Approved for Listing on the NASDAQ Capital Market
May 28, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Presentation of Phase 1 Data for Single-Agent Ublituximab (TG-1101) at the American Society of Clinical Oncology Meeting on June 2, 2013
May 16, 2013
 · 
1 min read
Business
TG Therapeutics, Inc. Announces First Quarter 2013 Financial Results and Business Update
May 14, 2013
 · 
1 min read
Business
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2013 Financial Results and Business Update
May 10, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Present at the 12th Annual Needham Healthcare Conference
April 30, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Present at the 25th Annual ROTH Conference
March 18, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Initiates First-In-Human, Phase I Clinical Trial for Its Novel, Highly Specific PI3K-Delta Inhibitor, TGR-1202, in Patients With Hematologic Malignancies
January 8, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference
January 7, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces FDA Clearance to Commence Clinical Trials of Its Novel, PI3K-Delta Specific Inhibitor, TGR-1202, Under Its Recently Filed U.S. Investigational New Drug (IND) Application
January 3, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference
December 11, 2012
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab (TG-1101) and TGR-1202 From the 54th American Society of Hematology Meeting
December 10, 2012
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS